{"type":"trials","record":{"id":41623,"source_id":"clinicaltrials-gov","external_id":"NCT07305298","title":"Mirabegron in Patients With Age-Related Macular Degeneration","brief_summary":"The goal of this clinical trial is to learn if Mirabegron works to treat dry AMD in patients, aged between 50 and 80 years-old, with early or moderate dry AMD and overactive bladder. The main question it aims to answer is: • Is there any change in outer retina morphology in patients treated? Researchers will compare the safety and efficacy of mirabegron versus conventional approach (Solifenacin) to treat dry AMD in patients with dry AMD and overactive bladder. Participants will: * Take Mirabegron or Solifenacin every day for 12 months * Visit the clinic once every 6 months for checkups and tests","overall_status":"Not Yet Recruiting","phases":[],"study_type":"OBSERVATIONAL","sponsor":"University of Naples","enrollment":312,"countries":["Italy"],"start_date":"2026-04-01","completion_date":"2026-12-01","last_update_date":"2026-02-06","source_url":"https://clinicaltrials.gov/study/NCT07305298","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years to 80 Years","comparator":null,"organization":"University of Naples","interventions":["Mirabegron 50mg","Solifenacin 5mg"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Changes in outer retinal morphology using SD-OCT — \"From enrollment to the end of treatment at 12 months","Changes in FAF assessing — \"From enrollment to the end of treatment at 12 months","mean BCVA — From enrollment to the end of treatment at 12 months","Mean macular sensitivity (MS) — From enrollment to the end of treatment at 12 months"],"design_description":null,"source_has_results":false},"controlled_terms":["Dry AMD","Overactive Bladder","Mirabegron 50mg","Solifenacin 5mg"],"relevance_confidence":80,"source_quality_score":100,"freshness_score":85,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct07305298","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2026-04-01 to 2026-12-01","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years to 80 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.843Z","intervention":["Mirabegron 50mg","Solifenacin 5mg"],"participants":312,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Changes in outer retinal morphology using SD-OCT — \"From enrollment to the end of treatment at 12 months","Changes in FAF assessing — \"From enrollment to the end of treatment at 12 months","mean BCVA — From enrollment to the end of treatment at 12 months","Mean macular sensitivity (MS) — From enrollment to the end of treatment at 12 months"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["title","title context","study type"],"relevance_score":80,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41623","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}